|Articles|May 15, 2003
- BioPharm International-05-01-2003
- Volume 16
- Issue 5
Demonstrating the Consistency of Small Data Sets: Application of the Weisberg t-test for Outliers
by Robert J. Seely, Amgen, Inc. Louis Munyakazi, John Haury, Heather Simmerman, W. Heath Rushing, and Thomas F. Curry Determining whether a data point is an "outlier" ? a result that doesn't fit, that is too high or too low, that is extreme or discordant ? is difficult when using small data sets (such as the data from three, four, or five conformance runs). The authors show that the Weisberg t-test is a powerful tool for detecting deviations in small data sets.
Advertisement
Articles in this issue
over 22 years ago
Sumeria to Satellites: Evolution of the Bioreactorover 22 years ago
Patent Law: Extracting Maximum Value from Your Patent Portfolioover 22 years ago
Inside Washington: Medication Safety in the Limelightover 22 years ago
Part 11 Is Not Going Away: The New Electronic Records Draft Guidanceover 22 years ago
Survival Strategies: The Life Sciences Industry Turns to eLearningNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
2
Cellares Extends Cell Therapy Automation Beyond T Cell Therapies
3
Containment to Protection: Packaging Trends Impacting Biopharma
4
FDA Clears Affinia’s AFTX-201 for Phase I/II BAG3 Cardiomyopathy Trial
5
